ChromaDex (NASDAQ:CDXC) Downgraded to Buy Rating by StockNews.com

StockNews.com downgraded shares of ChromaDex (NASDAQ:CDXC) from a strong-buy rating to a buy rating in a report issued on Friday morning.

CDXC has been the topic of several other research reports. Roth Mkm upped their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright upped their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th.

ChromaDex Stock Performance

Shares of NASDAQ:CDXC opened at $5.51 on Friday. ChromaDex has a 52 week low of $1.36 and a 52 week high of $7.97. The company’s fifty day moving average is $6.29 and its 200-day moving average is $4.25. The company has a market capitalization of $420.87 million, a PE ratio of 551.55 and a beta of 2.21.

ChromaDex (NASDAQ:CDXC) last issued its earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The company had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the previous year, the company earned ($0.01) EPS. On average, analysts forecast that ChromaDex will post 0.04 EPS for the current year.

Insiders Place Their Bets

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 9.64% of the company’s stock.

Institutional Trading of ChromaDex

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company bought a new stake in shares of ChromaDex in the 2nd quarter valued at about $31,000. Merriman Wealth Management LLC bought a new stake in shares of ChromaDex in the 2nd quarter valued at about $32,000. FMR LLC bought a new stake in shares of ChromaDex in the 3rd quarter valued at about $55,000. Marshall Wace LLP bought a new stake in shares of ChromaDex in the 2nd quarter valued at about $56,000. Finally, SG Americas Securities LLC bought a new stake in shares of ChromaDex in the 3rd quarter valued at about $61,000. 15.41% of the stock is owned by institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.